DNAJC8

Across TCGA pan-cancer cohorts, DNAJC8 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DNAJC8 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DNAJC8 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DNAJC8 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where DNAJC8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.991	0.738	<.001	65	view →
PDAC	DFS	Median	All	0.925	0.680	.001	21	view →
HNSC	DFS	Median	III,IV	0.510	0.763	.012	5	view →
CCRCC	DFS	Quartile	II,III,IV	0.908	0.589	.025	5	view →
LSCC	DFS	Median	All	0.929	0.615	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DNAJC8–LUAD (OS)

Open the LUAD breakdown →